Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics reported a significant revenue increase of 209% to US$3.4 million for Q1 FY25, driven by strong growth in product and services revenue. The company also secured a successful A$10 million capital raise and announced a promising partnership with BARDA for non-dilutive funding to support the FebriDx CLIA waiver trial in the U.S. This strategic move, along with new distributor agreements, positions Lumos for substantial U.S. market expansion.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.